Evaluation of 3 SARS-CoV-2 IgG Antibody Assays and Correlation with Neutralizing Antibodies

Jenna Rychert, Marc Roger Couturier, Marc Elgort, Bucky Ken Lozier, Sonia La'ulu, Jonathan R. Genzen, Joely A. Straseski, Julio C. Delgado, and Patricia R. Slev

Background: As serologic assays for SARS-CoV-2 become more widely utilized, it is important to understand their performance characteristics and correlation with neutralizing antibodies. We evaluated 3 commonly used SARS-CoV-2 IgG assays (Abbott, DiaSorin, and EUROIMMUN) for clinical sensitivity, specificity, and correlation with neutralizing antibodies, and then compared antibody kinetics during the acute phase of infection.

Methods: Three panels of samples were tested on every assay. Sensitivity was assessed using a panel of 35 specimens serially collected from 7 patients with RT–PCR-confirmed COVID-19. Specificity was determined using 100 sera samples collected in 2018 from healthy individuals prior to the outbreak. Analytical specificity was determined using a panel of 37 samples from individuals with respiratory illnesses other than COVID-19.

Results: Clinical sensitivity was 91.43% (95% CI 76.94–98.20%) for Abbott, and 88.57% (95% CI 73.26–96.80%) for both DiaSorin and EUROIMMUN. Clinical specificity was 99.00% (95% CI 94.55–99.97%) for Abbott and DiaSorin and 94.00% (95% CI 87.40–97.77%) for EUROIMMUN. The IgG assays demonstrated good qualitative agreement (minimum of 94%) and good correlation between the quantitative result for each combination of assays ($r^2 > 0.90$). The neutralizing antibody response did not necessarily follow the same temporal kinetics as the IgG response and did not necessarily correlate with IgG values.

Conclusion: The 3 IgG antibody assays demonstrated comparable performance characteristics. Importantly, a qualitative positive IgG result obtained with any of the assays was associated with the presence of neutralizing antibodies; however, neutralizing antibody concentrations did not correlate well with signal to cutoff ratios.

INTRODUCTION

The recent increase in the availability and use of serologic assays for detecting antibodies against SARS-CoV-2 is enabling a more thorough understanding of the broader epidemiology of COVID-19 infections and provides a more accurate estimate of local prevalence and disease incidence. However, the increase in testing options has also led to many questions. Clinicians and
laboratorians are inundated with options for COVID antibody testing, ranging from rapid tests to laboratory based ELISAs and chemiluminescent immunoassays (CIAs). While the FDA has facilitated a more rapid pathway to the US market through updates to the EUA process, independent evaluation and verification of the performance characteristics of the remaining available assays are critical for guiding utilization. The aim of our studies was twofold. First, we aimed to evaluate the performance of 3 widely utilized SARS-CoV-2 IgG commercial assays, the Abbott SARS-CoV-2 IgG, DiaSorin Liaison SARS-CoV-2 S1/S2 IgG, and the Anti-SARS-CoV-2 IgG ELISA from EUROIMMUN. Second, we wanted to determine whether these assays could be used to predict the neutralizing antibody response. The antibody response that develops in response to SARS-CoV-2 infection consists of both binding and neutralizing antibodies. Neutralizing antibodies are crucial for preventing infection and are believed to play a key role in putative immunity. However, these assays are time consuming, labor intensive, require expertise, are expensive, and are not amenable to mass screening protocols. The currently available commercial antibody assays measure both types of antibodies (binding and neutralizing) and are more readily implemented in the clinical laboratory. Therefore, determining correlation between the current high-throughput antibody assays and neutralizing antibodies, which are essential for any protective immunity, is critical.

MATERIALS AND METHODS

Samples

A total of 35 samples were collected from 7 adults (age range 39–79, 29% female) confirmed positive for COVID-19 by an FDA authorized (EUA) SARS-CoV-2 RT–PCR assay at ARUP Laboratories (ARUP). Remnant serum or plasma samples from these individuals were collected from March to May 2020 based on availability and in accordance with IRB approved protocol 0007275.

A total of 100 healthy donor samples collected prior to August 2019, before the start of the outbreak, were used to evaluate clinical specificity. This included deidentified residual serum from 80 adult (age range 20–68 years old, 49% female) and 20 pediatric patients (age range 2–18 years old, 40% female). An additional 37 samples from individuals (age range 1–93, 49% female) with respiratory illnesses other than COVID-19 obtained between February and March 2020 were included to assess cross-reactivity (analytical specificity).

IgG Antibody Testing

All specimens in each panel were tested using all 3 IgG immunoassays. The Abbott SARS-CoV-2 IgG assay was performed on the Abbott Architect i2000 (Abbott Laboratories Inc, Abbott Park) according to the manufacturer’s instructions. This is a qualitative chemiluminescent microparticle immunoassay that detects IgG to the
nucleocapsid protein of SARS-CoV-2. According to the manufacturer, there is a direct relationship between the amount of SARS-CoV-2 specific IgG in the sample and the calculated signal of the sample divided by the signal of the calibrator (S/C) index. A result is considered positive if the S/C is greater than or equal to 1.4. The DiaSorin Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin) was performed on the DiaSorin XL according to the manufacturer's instructions. This is a qualitative indirect chemiluminescent immunoassay that detects IgG bound to recombinant spike protein S1 and S2 domains. Antibody concentration is expressed as arbitrary units (AU/mL) with an assay range up to 400 AU/mL. Results are interpreted as positive if the AU/mL are greater than or equal to 15.0. The EUROIMMUN assay was performed manually according to the manufacturer's instructions using the Anti-SARS-CoV-2 IgG Enzyme Linked Immunosorbent Assay (EUROIMMUN). The assay format is a 96-well microtiter plate coated with SARS-CoV-2 recombinant S1 spike protein produced in HEK 293 cells. Results are calculated as the ratio between the absorbance of the sample and the absorbance of the calibrator. This sample to calibrator ratio is interpreted as negative when the ratio is below 0.8, borderline if the ratio is between 0.8 and 1.1, and positive if the ratio is greater than or equal to 1.1. Results were interpreted according to the manufacturer’s cutoffs, unless otherwise indicated.

Neutralizing Antibody Testing

All specimens were tested for neutralizing antibody at Vyriad, Inc. using their Immuno-CoV assay (1). This is a quantitative test that measures neutralizing antibodies against a recombinant Vesicular Stomatitis Virus encoding the spike glycoprotein of SARS-CoV-2. The neutralizing antibody concentration is expressed as virus neutralizing units (VNU) and is determined using a calibration curve consisting of an anti-SARS-CoV-2 monoclonal antibody spiked into pooled seronegative serum. VNU’s correlate with plaque reduction neutralization titer half maximal effective concentration (PRNT<sub>EC50</sub>) values.

Statistical Analysis

Statistical analysis was performed using GraphPad Prism (v.8.4.2). Sensitivity was calculated using molecular testing as the reference method. Specificity was calculated using samples from healthy individuals. Borderline results on the EUROIMMUN IgG assay were considered negative unless otherwise indicated.

RESULTS

Clinical Sensitivity

Sensitivity was calculated based on testing 35 specimens from 7 COVID-19 RT-PCR positive individuals. Differences in sensitivity observed between the 3 assays are summarized in Table 1. Of the 10 samples collected less than 7 days post RT-PCR confirmed diagnosis, 3 samples were not detected by any of the assays. One additional sample, collected day 5 post RT-PCR, was positive on the Abbott assay but negative by DiaSorin and EUROIMMUN. The S/C ratio was 1.49 (positive cutoff for this assay is 1.4). The remaining 25 samples collected more than 7 days post RT-PCR were positive on all 3 platforms. Considering all samples tested, regardless of timing post diagnosis by RT-PCR, the sensitivity of the Abbott assay was 91.43% (95% CI 76.94–98.20%), while the sensitivity of the DiaSorin and EUROIMMUN assays were both 88.57% (73.26–96.80%).

Clinical Specificity

The clinical specificity for the 3 assays was calculated using 100 samples from self-reported healthy individuals collected prior to the pandemic are presented in Table 1. Briefly, 90 of these samples were negative on all 3 platforms. Among
the remaining 10 samples, one tested positive by Abbott (S/C = 1.73), another tested positive by DiaSorin (AU/mL = 15.6), 6 tested positive by EUROIMMUN (S/C = 1.1, 1.1, 1.7, 2.2, 2.3, 3.2), and the remaining 4 samples were borderline by EUROIMMUN (S/C = 0.8, 0.9, 1.0, 1.0). All the false-positive test results were unique to a single platform and specimen. The clinical specificity of the Abbott and DiaSorin assays was 99.00% (95% CI 94.55–99.97%), as each assay had one false-positive result. For EUROIMMUN the specificity was 94.00% (95% CI 87.40–97.77%) when borderline results were considered negative. If borderline results were considered positive, the specificity of EUROIMMUN was 90% (95% CI 82.38–95.10%).

### Analytical Specificity

To further explore possible false-positive results in individuals who may experience symptoms consistent with COVID-19, but are infected with other common respiratory viruses, we also tested a panel of serum samples from individuals who were tested for respiratory illnesses other than COVID-19. Among the 37 samples tested, all were negative on both the Abbott (average S/C = 0.06) and DiaSorin (average AU/mL = 2.35) assays. On the EUROIMMUN assay, 34 tested negative (average S/C = 0.04), one sample was borderline (S/C = 1.0), and 2 samples were positive with S/C of 1.1 and 2.5 (Table 2).

### Performance Characteristics and Disease Prevalence

Given that the current prevalence of SARS-CoV-2 infection is low in some areas in the US, there is a high likelihood of false positives, even for assays that have high specificity. With this in mind, we calculated the positive and negative predictive values for each of the assays, assuming a prevalence of COVID-19 of 5% and using our sensitivity and specificity findings. Under this assumption, the negative predictive values were similar for all 3

---

**Table 2.** Comparison of performance characteristics for the 3 commercially available SARS-CoV-2 assays.

| Serology Assay | IgG positive > 7 days post RT-PCR n = 25 | IgG positive < 7 days post RT-PCR n = 10 | IgG negative n = 100 | SARS-CoV-2 PCR + Healthy | Sensitivity | Specificity | Positive likelihood ratio | Negative likelihood ratio | PPV at 5% prevalence | NPV at 5% prevalence |
|----------------|------------------------------------------|------------------------------------------|----------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Abbott         | 25/25                                    | 25/25                                    | 99/100               | 1.1%                     | 99.00%                   | 99.00%                   | 99.00%                   | 99.00%                   | 99.00%                   | 99.00%                   |
| DiaSorin       | 25/25                                    | 25/25                                    | 99/100               | 0.1%                     | 99.00%                   | 99.00%                   | 99.00%                   | 99.00%                   | 99.00%                   | 99.00%                   |
| EUROIMMUN      | 25/25                                    | 25/25                                    | 99/100               | 0.0%                     | 99.00%                   | 99.00%                   | 99.00%                   | 99.00%                   | 99.00%                   | 99.00%                   |

*Borderline results were considered negative.

---

May 2021 | 06:03 | 614–624 | JALM 617
platforms 99.55, 99.40, and 99.36% for Abbott, DiaSorin, and EUROIMMUN, respectively. The positive predictive values were similar for Abbott and DiaSorin (82.79 and 82.34%, respectively), but much lower for EUROIMMUN (43.72%). To improve the positive predictive value of testing in low prevalence settings, the CDC currently recommends an orthogonal testing algorithm, such that samples that test positive by one assay are tested with another assay that has a different antigen or format (2). Using the online calculator provided with the CDC guidance statement, at a prevalence of 5%, the estimated positive predictive value increases to >98% regardless of which 2 tests are used. In addition, less than 2% of samples would have discordant results using this type of algorithm with any 2 of these assays.

When compared against each other, the overall agreement for Abbott and DiaSorin was 98.26% with a positive percentage agreement of 96.88% and a negative percentage agreement of 98.57% (Table 2). The overall agreement for EUROIMMUN in comparison to Abbott and DiaSorin was 94.19 and 94.77%, respectively. The positive percentage agreement was 79.49% for both comparisons and the positive percent agreement was 98.50% for Abbott vs EUROIMMUN and 99.25% for DiaSorin vs EUROIMMUN. Although these assays are intended to be reported qualitatively, we also compared the AU/mL (DiaSorin) or S/C Abbott and (EUROIMMUN) to determine whether quantitative values correlated. As shown in Fig. 1, linear regression analysis showed that the correlation between assays was good with an $r^2$ value of 0.91.

### Table 2. Concordance between 3 IgG SARS-CoV-2 assays.

|                  | Overall agreement (95% confidence interval) | Positive percentage agreement (95% confidence interval) | Negative percentage agreement (95% confidence interval) |
|------------------|--------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
| Abbott vs DiaSorin | 98.26% (94.99 to 99.64%)                   | 96.88% (83.78 to 99.92%)                              | 98.57% (94.93 to 99.83%)                               |
| Abbott vs EUROIMMUN | 94.19% (89.57 to 97.18%)                   | 79.49% (63.54 to 90.70%)                              | 98.50% (94.67 to 99.82%)                               |
| DiaSorin vs EUROIMMUN | 94.77% (90.30 to 97.58%)                   | 79.49% (63.54 to 90.70%)                              | 99.25% (95.88 to 99.98%)                               |

### Fig. 1. Correlation between assays. Comparison of the ratio of the signal to calibrator (S/C) or arbitrary units (AU/mL) for each combination of assays were plotted against each other and the correlation coefficient was calculated; a) Abbott compared to EUROIMMUN, b) Abbott compared to DiaSorin, and c) DiaSorin compared to EUROIMMUN. Dashed lines indicate the manufacturer-derived cutoff for the assay.
for Abbott and EUROIMMUN, 0.91 for Abbott and DiaSorin, and 0.92 for DiaSorin and EUROIMMUN. Results that were qualitatively discrepant were near the cutoff and largely represented either samples collected within a week of confirmation of COVID-19 by RT–PCR or the unique, assay specific false-positive samples.

Neutralizing Antibodies

We next measured neutralizing antibody responses against SARS-CoV-2 using the same panels of samples to assess the relationship between neutralizing antibodies and IgG as determined by the 3 commercial assays. Among the 35 samples from COVID-19 RT–PCR positive individuals, 32 tested positive for neutralizing antibodies, 2 tested negative, and one had insufficient volume to perform testing. The 2 samples that tested negative were collected within a week of confirmation by RT–PCR and were negative for IgG on all 3 assays. All 100 samples, comprising the panel used to determine specificity, tested negative for neutralizing antibodies. Among the 37 samples included in the cross-reactivity panel, 29 tested negative, 6 tested positive for neutralizing antibodies, and 2 had insufficient volume for testing. All 6 that tested positive had very low neutralizing antibody results, which were near the limit of detection of the assay. Five of these tested negative on all 3 of the IgG assays, the other was negative on Abbott (S/C = 0.04) and DiaSorin (AU/mL = 4.72) and indeterminate on EUROIMMUN (S/C = 1.0).

Receiver-Operating Characteristic (ROC) Curves

We also performed ROC area under the curve analysis for the Abbott, DiaSorin, and EUROIMMUN IgG assays using the qualitative neutralizing antibody result as the reference standard. The area under the curve was high for all 3 assays (0.94, 0.97, and 0.93 for Abbott, DiaSorin, and EUROIMMUN, respectively) (Fig. 2). At the manufacturer-derived cutoffs (Table 3), Abbott had a sensitivity of 84.21% (95% CI 68.75–93.98%)
and a specificity of 99.24% (95% CI 95.82–99.98%). DiaSorin had a sensitivity of 78.95% (95% CI 62.68–90.45%) and a specificity of 99.24% (95% CI 95.82–99.98%). EUROIMMUN had a sensitivity of 81.58% (95% CI 65.67–92.26%) and a specificity of 93.89% (95% CI 88.82–97.33%). If the EUROIMMUN cutoff was adjusted to 2.6, the specificity of the assay would be equivalent to that of the Abbott and DiaSorin assays at 99.24 (95% CI 95.82–99.98%). However, this would reduce the sensitivity to 76.32% (95% CI 59.76–88.56%) for EUROIMMUN. At the manufacturer-derived cutoffs, the overall qualitative agreement between each of the IgG assays and neutralizing antibody was 95.86, 94.67, and 91.12% for Abbott, DiaSorin, and EUROIMMUN, respectively. Using a cutoff of 2.6 for EUROIMMUN, the overall agreement increased to 94.08%, more closely matching that of Abbott and DiaSorin (Table 3).

**Antibody Kinetics**

Because we had samples drawn from the same individuals at various time points, we were also able to analyze the antibody kinetics as determined by each assay. The range of days post RT-PCR confirmation was 0 to 21 days post RT-PCR. Importantly, once an assay detected an IgG response, all subsequent time points were also positive. Across all 3 commercial IgG assays the magnitude of the IgG response was low within the first week, then generally increased over time, reaching a plateau around 2 weeks post RT-PCR. The neutralizing antibody responses did not follow the same temporal kinetics and the response was quite variable between different individuals and did not necessarily correlate with IgG serial values (Fig. 3).

**DISCUSSION**

In this study we evaluated 3 commercially available SARS-CoV-2 IgG serologic tests for sensitivity, specificity, and correlation with neutralizing...
antibodies. Sensitivity studies showed that there were no significant differences between the assays, as indicated by the overlapping confidence intervals. The overall sample set was small and the observed difference in sensitivity between the assays was due to one sample collected day 5 post RT-PCR that was detected by Abbott (borderline result) and failed to be detected by both...
DiaSorin and EUROIMMUN. Specificity studies showed EUROIMMUN had more false-positive results in healthy individuals, as well as in the cross-reactivity study, even when considering borderline results as negative. An increased number of false-positive results have been observed by our laboratory and others (3, 4). Overall, data from this study showed that clinical sensitivity and specificity of each of the 3 commercial IgG assays evaluated were generally comparable and agreed with data provided by the FDA and others (4–10). This is despite the fact that these assays use different methods (chemiluminescent immunoassay, ELISA) and different antigens (Abbott—nucleocapsid protein, DiaSorin—S1 and S2 domain of spike protein, EUROIMMUN—S1 domain of spike protein). While there has been a concern of false positives due to cross-reactivity with the common human coronaviruses, few if any studies have shown this to be the case (11). This may be because both the spike and nucleocapsid proteins only share about 30% amino acid identity with the common human coronaviruses (12).

In low prevalence settings, even a test with high specificity will generate false-positive results. Based on our analysis, the Abbott assay would likely generate the fewest false-positive results. To reduce the likelihood of reporting a false positive, the CDC has suggested performing orthogonal testing. Based on the performance characteristics we and others have observed, this strategy increases the positive predictive value of testing while maintaining a low likelihood of discordant results. The downside of this approach is the additional cost and turnaround time (13). However, there is also a possibility that discrepant results between assays may represent a true prior infection and may be due to differences in sensitivity between antibody assays, particularly, if the sample is collected too soon after symptom onset or a difference in the antigen used to capture antibodies. Seroconversion to some antigens, but not others has been observed in at least one study (8). However, currently, there is no indication that using antigens representing the nucleocapsid or spike to detect IgG antibodies significantly affects assay performance.

In addition, although we detected seroconversion in all patients by 7 days post RT–PCR using all 3 assays, some studies have identified individuals in whom seroconversion was delayed (10, 14) or did not occur at all (4, 15, 16). We and others found that once an individual seroconverts, the IgG response does increase over the first few weeks of infection and then plateaus (4, 10, 15–17). As the coronavirus pandemic continues, additional data will need to be collected to determine the kinetics and longevity of the IgG response.

Finally, because neutralizing antibodies (Nab) are implicated in providing possible immunity, we aimed to correlate neutralizing antibodies with the IgG values obtained with the different IgG assays. The data demonstrated that in our study cohort, neutralizing antibodies developed early during the course of infection and the presence of IgG predicted a neutralizing antibody response. The concentration of neutralizing antibodies did not correlate well with the level of anti-SARS-CoV-2 IgG, as measured by either of the 3 assays. Others have also reported the early development of neutralizing antibody responses but did find a correlation between neutralizing antibody responses and IgG (3, 7, 12, 17). Wide variation in the degree of neutralizing activity has also been reported (8, 18). Furthermore, our data suggest that the current cutoffs for Abbott and DiaSorin are appropriate for discriminating neutralizing antibody positive from neutralizing antibody-negative samples. However, based on our data, an adjustment of the cutoff for EUROIMMUN would be needed for this test to perform similarly. There is increasing evidence that neutralizing antibodies may mediate at least some degree of immunity. SARS-CoV-2 specific neutralizing antibodies have been detected in individuals who have recovered from COVID-19 and COVID-19 convalescent
plasma (CCP) from recovered individuals has shown promise as a treatment (19–21). In a Rhesus macaque model, animals developed both binding and neutralizing antibodies and were protected from reinfection by SARS-CoV-2 (22, 23). Correlation between neutralizing antibodies and IgG values obtained with various commercial assays is an important area of study, as it may have implications for clinical decisions, for example, when a vaccine becomes available.

This study is limited due to the small number of samples from patients who tested positive for SARS-CoV-2 and the lack of samples from patients infected with other coronaviruses. However, our results are consistent with other similar studies and with the manufacturers’ performance claims. Another limitation is the retrospective study design and lack of clinical data, which does limit the analysis of the kinetics of the IgG and neutralizing antibody response. It is also not clear, based on our data, whether the variation observed between individuals is due to variation in severity of disease and/or immune response to different antigenic targets. Additional studies will be needed to clarify the factors that contribute to the variation in antibody responses and the development of a robust and protective immune response.

In conclusion, our study demonstrated that 3 EUA designated SARS-CoV-2 assays had comparable performance characteristics that were consistent with manufacturer claims. Although not statistically significant due to our sample size, in our study EUROMMUN did have more false-positive results than Abbott and DiaSorin, even when borderline samples were considered negative. Our data also indicate that the cutoffs for Abbott and DiaSorin are appropriate for discriminating neutralizing antibody positive from neutralizing antibody-negative samples. Importantly, we found no correlation between IgG Au or S/C values and concentration of neutralizing antibodies. Although, the findings in this study are consistent with manufacturer claims, the study provides useful information for laboratories that are still considering what platform to use for SARS-CoV-2 antibody testing. Continued independent evaluation of SARS-CoV-2 serologic assays is key as we learn more about individual variations in response to SARS-CoV-2 infection, we develop vaccines, and as testing guidelines evolve.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.

J. Rychert, statistical analysis; P.R. Slev, statistical analysis, administrative support, provision of study material or patients.

Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest: Employment or Leadership: J.R. Genzen, University of Utah, ARUP Laboratories. Consultant or Advisory Role: P.R. Slev, Euroimmun. Stock Ownership: None declared. Honoraria: None declared. Research Funding: Abbott and DiaSorin provided kits for evaluation. Expert Testimony: None declared. Patents: None declared.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, preparation of manuscript, or final approval of manuscript.

Acknowledgments: We would like to thank Hailey Wells for her help with collecting and aliquoting samples. We would like to thank Abbott and DiaSorin for providing kits for evaluation.
REFERENCES

1. VanderGaast R, Carey T, Reiter S, Lech P, Gnanadurai C, Tesfay M, et al. Development and validation of ImmunoCov™: A high-throughput clinical assay for detecting antibodies that neutralize SARS-COV-2. Preprint at https://www.biorxiv.org/content/10.1101/2020.05.26.117549v1 (2020).

2. Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing. IN: CDC. 2020.

3. Jaaskelainen AJ, Kekalainen E, Kallio-Kokko H, Mannonen L, Kortela E, Vapalahti O, et al. Evaluation of commercial and automated SARS-COV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples. Eurosurveillance 2020;25:2000603.

4. Tang M S, Hock K G, Logsdon N M, Hayes J E, Gronowski A M, Anderson N W, Farnsworth C W. Clinical Performance of two SARS-CoV-2 serologic assays. Clin Chem 2020;66:1055–62. 10.1093/clinchem/hvaa120

5. US Food and Drug Administration. EUA authorized serology test performance. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance (Accessed November 9, 2020).

6. Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, et al. Clinical and analytical performance of an automated serological test that identifies S1/S2 neutralizing IgG in COVID-19 patients semiquantitatively. J Clin Microbiol 58:e01224–20

7. Geurtsvankessel CH, Okba NMA, Igloi Z, Embregts CWE, Laksono BM, Leijten L, et al. Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment. Preprint at https://www.medrxiv.org/content/10.1101/2020.04.23.20077156v2 (2020).

8. Luchsinger LL, Ransegnola B, Jin D, Muecksch F, Weisblum Y, Bao W, et al. Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients. J Clin Microbiol 2020;doi:10.1128/JCM.02005-20

9. Beavis K G, Matushek S M, Abeledo A P F, Bethel C, Hunt C, Gillen S, et al. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies. J Clin Virol 2020;129:104468 10.1016/j.jcv.2020.104468

10. Theel ES, Harring J, Hilgart H, Granger D. Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2. J Clin Microbiol 2020;58:jcm.0124320.

11. Espejo AP, Akgun Y, Al Mana AF, Tjendra Y, Millan NC, Gomez-Fernandez C, Cray C. Review of current advances in serologic testing for COVID-19. Am J Clin Pathol 2020;154:293–304.

12. Okba NMA, Müller MA, Li W, Wang C, Geurtsvankessel CH, Corman VM, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg Infect Dis Vol. 26, No.7, July 2020.

13. American Clinical Laboratory Association. ACLA letter to CDC on antibody guidance (June 15, 2020). www.acla.com/covid-19/ (Accessed June 2020).

14. Ng D, Goldgof G, Shy B, Levine A, Balcerjak J, Bapat SP, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. Nat Commun 2020;doi: 10.1038/s41467-020-18468-8.

15. Brandsdikster S, Roth S, Harner S, Buntrock-dopke H, Toncheva A A, Borchers N, et al. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak. Pediatr Allergy Immunol 2020;31:841–7. 10.1111/pai.13278

16. Long Q-X, Deng H-J, Chen J, Hu J, Liu B-Z, Liao P, et al. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. Nat Med 2020;26:845–8.

17. Suthar MS, Zimmerman M, Kauffman R, Mantus G, Linderman S, Vanderheiden A, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med 2020;doi: 10.1016/j.xcrm.2020.100040.

18. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Preprint at https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v2 (2020).

19. Bloch EM, Shoham S, Casadevall A, Sachs BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020;130:2757–65.

20. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020;117: 9490–6.

21. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582–9.

22. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Lack of reinfection in rhesus macaques infected with SARS-CoV-2. Preprint at https://www.biorxiv.org/content/10.1101/2020.03.13.990226v2 (2020).

23. Chandrashekar A, Liu J, Martinez AJ, McMahan K, Mercado NB, Peter L, et al. SARS-COV-2 infection protects against rechallenge in rhesus macaques. Science 2020;eabc4776.